China Diagnostic Reagent Industry Report, 2012-2014

DUBLIN, Ireland, March 26, 2013 /PRNewswire/ --

Research and Markets announces the addition of "China Diagnostic Reagent Industry Report, 2012-2014" to its catalogue.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

China's diagnostic reagent industry has formed a certain market scale and basis, and is marching from the introduction stage to the growth stage. With the continuous growth in China's medical care investment and per capita health care spending, the China's diagnostic reagent market has a promising prospect.

In vitro diagnostic reagents account for more than 90.0% of the output of China's diagnostic reagent industry. In 2011, the market scale of in vitro diagnostic reagents reached about RMB 11.4 billion in China, the industry will maintain a growth rate of 15%-20% in the future, and the market scale will hit RMB 20.8 billion in 2015.

At present, there are only a few integrated in vitro diagnostic reagent enterprises with strong strength in China's diagnostic reagent market, including KHB and Fosun Pharma; other enterprises such as Da An Gene, BioSino, Leadman and Livzon have competitive advantages in specific fields such as biochemical diagnosis, immunodiagnosis, and molecular diagnosis.

Meanwhile, China's in vitro diagnostic reagent industry concentration is low. Among 300-400 enterprises, there are only about 20 enterprises with annual sales of more than RMB 100 million. The enterprises are generally small and have a few product varieties. In 2011, KHB, Da An Gene, BioSino, Leadman only occupied 3.8%, 2.3%, 1.9%, 1.6% of the market respectively.

Key Topics Covered:

1. Overview of Diagnostic Reagent Industry

2. China Diagnostic Reagent Industry
2.1 Overview
2.2 Market Structure
2.3 Import and Export
2.3.1 Import
2.3.2 Export
2.4 Competitive Landscape
2.4.1 Biochemical Diagnostic Reagents
2.4.2 Immune Diagnostic Reagents
2.4.3 Molecular Diagnostic Reagents
2.4.4 Integrated In Vitro Diagnostic Reagents
2.5 Profitability
2.6 Entry Barriers
2.6.1 Technical Barriers
2.6.2 Quality and Brand Barriers
2.6.3 Marketing Channel Barriers
2.6.4 Market Access Barriers

3. Development Environment of China Diagnostic Reagent Industry
3.1 Policy Environment
3.1.1 Regulatory Policy
3.1.2 Industry Policy
3.2 Upstream and Downstream Industries
3.2.1 Industrial Chain
3.2.2 Upstream
3.2.3 Downstream

4. Development Forecast of China Diagnostic Reagent Industry
4.1 Overall Forecast
4.1.1 Market Demand Drivers
4.1.2 Market Scale Forecast
4.2 Development Trends of Diagnostic Reagent Industry
4.2.1 Biochemical Diagnosis and Immunodiagnosis Will Still Be the Mainstream
4.2.2 Industry Concentration Will Increase
4.2.3 Enterprises with Complete Product Line Integrating Reagents and Instruments will Win

5. Major Chinese Diagnostic Reagent Enterprises

Selected Charts

Companies Mentioned

- Acon Biotech (Hangzhou)
- Beijing Kinghawk Pharmaceutical
- Beijing Leadman Biochemistry
- Beijing North Institute of Biological Technology (BNIBT)
- Beijing Wantai Biological Pharmacy Enterprise
- BioSino Bio-technology and Science
- Blue Cross Bio-Medical (Beijing)
- Da An Gene
- Inverness Medical (Shanghai)
- Livzon Pharmaceutical Group
- Shanghai Fosun Pharmaceutical (Group)
- Shanghai Kehua Bio-engineering
- Shanghai Rongsheng Biotech
- Shanghai Upper Bio-Tech Pharma
- Shenzhen PG Biotech

For more information please visit Research and Markets.

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contact Details

Research and Markets
Laura Wood, Senior Manager.
press(at)researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Sector: Diagnostics

SOURCE Research and Markets